Add Company
Join Now

Gracell Biotechnologies Revenue and Competitors

License our Company Data API

上海市,

Location

N/A

Total Funding

Tech Services

Industry

Estimated Revenue & Valuation

  • Gracell Biotechnologies's estimated annual revenue is currently $1.2M per year.(i)
  • Gracell Biotechnologies's estimated revenue per employee is $101,500
  • Gracell Biotechnologies's current valuation is $309.8M. (January 2022)

Employee Data

  • Gracell Biotechnologies has 12 Employees.(i)
  • Gracell Biotechnologies grew their employee count by -37% last year.

Gracell Biotechnologies's People

NameTitleEmail/Phone
1
Executive Director Finance and Investor RelationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$57.6M31824%N/AN/A
#2
$44.6M28623%$25.4MN/A
#3
$5.1M44-6%N/AN/A
#4
$35.1M225-3%$46.9MN/A
#5
$14.5M1005%N/AN/A
#6
$1.3M15-6%N/AN/A
#7
$1.5M170%N/AN/A
#8
$2.9M29-12%N/AN/A
#9
$125.2M6916%N/AN/A
#10
$95.9M529-1%N/AN/A
Add Company

What Is Gracell Biotechnologies?

亘喜生物科技(上海)有限公司 is an information technology and services company based out of 上海市徐汇区宜山路926号1幢12层, 上海市, 上海市, China.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$1.2M

Revenue (est)

-37%

Employee Growth %

$309.8M

Valuation

N/A

Accelerator

Gracell Biotechnologies News

2022-04-13 - Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 ...

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual...

2022-04-06 - Gracell Biotechnologies to Present Data at AACR Annual ...

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL.

2022-03-30 - Gracell Biotechnologies to Participate in Three Investor ...

PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”),...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A12-8%N/A
#2
$1.5M120%N/A
#3
$1.1M120%N/A
#4
N/A129%N/A
#5
$1.1M13-32%N/A